160241-65-6

Basic information

• Product Name: 2-(2-METHYL-THIAZOL-4-YL)-PHENOL
• Synonyms: 2-(2-METHYL-THIAZOL-4-YL)-PHENOL;BUTTPARK 16\06-63;2-(2-methyl-1,3-thiazol-4-yl)phenol
• CAS NO: 160241-65-6
• Molecular Formula: C10H9NOS
• Molecular Weight: 191.25
• Mol File: 160241-65-6.mol

Chemical Properties

• Melting Point: 61-64℃
• Boiling Point: 331.2°Cat760mmHg
• Flash Point: 154.1°C
• Appearance: /
• Density: 1.257g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.629
• CAS DataBase Reference: 2-(2-METHYL-THIAZOL-4-YL)-PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-METHYL-THIAZOL-4-YL)-PHENOL(160241-65-6)
• EPA Substance Registry System: 2-(2-METHYL-THIAZOL-4-YL)-PHENOL(160241-65-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 160241-65-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-METHYL-THIAZOL-4-YL)-PHENOL is used as a key intermediate in the synthesis of pharmaceuticals for the development of new drugs and therapeutic agents. Its unique structure allows it to be a building block for the creation of various organic compounds with potential medicinal properties.
Used in Organic Chemistry:
In the realm of organic chemistry, 2-(2-METHYL-THIAZOL-4-YL)-PHENOL serves as a valuable intermediate for the synthesis of a wide range of organic compounds. Its ability to be modified and incorporated into more complex molecules makes it an essential component in the development of novel chemical entities with diverse applications.

InChI:InChI=1/C10H9NOS/c1-7-11-9(6-13-7)8-4-2-3-5-10(8)12/h2-6,12H,1H3

Upstream product

• 40231-08-1 o-(Bromoacetyl)phenyl acetate 
• 7250-94-4 o-acetoxyacetophenone 
• 118-93-4 o-hydroxyacetophenone 
• 62-55-5 thioacetamide 
• 2491-36-3 2-(2-bromoacetyl)hydroxybenzene 

Relevant articles and documents

NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF

Provided are a nitrogenous heterocyclic aromatic compound, a preparation method therefor, a pharmaceutical composition thereof, and an application thereof. The nitrogenous heterocyclic aromatic compound can be used for treating and/or preventing various diseases mediated by ALK5.

Organometallic complex

PROBLEM TO BE SOLVED: To provide an organometallic complex which has sufficient stability, can emit particularly blue to violet fluorescence etc. with high color purity, and can be used suitably e.g., as a luminescent material.SOLUTION: The organometallic complex is represented by the general formula (1). (X represents a sulfur atom, an oxygen atom, or a nitrogen atom that may have a substituent; a central metal atom M represents a metal atom belonging to one of groups 1 to 3, 12 and 13 in the periodic table; n is 2 or 3; and Rto Reach represents a hydrogen atom or a substituent.)

Synthesis and characterization of novel oxime derivatives

Background: The synthesis of effective drugs are very important for the scientist. The various biological effects of the thiazole, oxime and ether functional groups are well known properties by the drug developers. So we have synthesised new molecules which contains three of them on the same molecules. Methods: The acetophenone derivatives have been used for synthesis new oximes. The synthetic pathway includes mainly four steps. s1. α-Bromination of acetophenone derivatives, s2. Synthesis of thiazole ring using brominated acetophenones, s3. Synthesis of ethers using synthesised thiazole, s4. Synthesis of oximes. Results: The synthesised molecules characterised using IR,1H-NMR, 13C-NMR and elementel analysis methods. Conclusion: The new oximes which include thiazole and ether groups have been synthesised using acetophenone derivatives.

Compounds enhancing antitumor activity of other cytotoxic agents

This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).